A year-long, state-wide screening drive for non-communicable diseases has concluded in Andhra Pradesh, reaching 86.97 per cent of its target population and surfacing 59.29 lakh hypertension cases and 48.15 lakh diabetes cases — including more than 22 lakh new diagnoses — along with several thousand confirmed cancers, all placed on treatment protocols.
Andhra Pradesh’s Non-Communicable Diseases 4.0 (NCD 4.0) programme, a year-long, state-wide health screening drive, has concluded. Health minister Y. Satya Kumar Yadav confirmed on 1 September 2026 that the survey, which began on 17 September 2025, closed on 31 August 2026 after conducting health checks on 3,71,86,846 people — 86.97 per cent of the state’s targeted population. The scale places NCD 4.0 among the largest public-health screening exercises undertaken by any Indian state this year, and its conclusion offers the clearest picture yet of the state’s underlying non-communicable disease burden.
The headline numbers are substantial. Of those screened, 59.29 lakh people were found to have high blood pressure, including 11.79 lakh cases identified for the first time. A further 48.15 lakh people were found to have diabetes, including 10.72 lakh new diagnoses. Andhra Pradesh’s health department said all confirmed cases — new and previously known — have been placed on immediate treatment protocols, continuing the state’s practice under earlier NCD screening rounds of linking screening directly to primary-care follow-up rather than leaving detection as a standalone exercise.
Cancer screening
NCD 4.0 also screened for India’s three most common government-programme cancers — oral, breast and cervical. The initial screening round flagged 22,110 people with suspected oral cancer, 14,822 with suspected breast cancer and 18,837 with suspected cervical cancer. Confirmatory testing at district teaching hospitals subsequently validated a much smaller — but still significant — subset: 2,026 confirmed oral cancers, 3,571 confirmed breast cancers and 2,076 confirmed cervical cancers. The roughly ten-to-one ratio between suspected and confirmed cases across all three cancer types is in line with what population-level screening programmes typically produce, where an initial low-cost, high-sensitivity screen (visual inspection, clinical breast examination, VIA testing) is deliberately designed to over-flag, with a second, more specific diagnostic stage at district hospitals filtering out false positives before treatment begins.
A district-level puzzle
The specific news hook for the minister’s remarks was a comparison across districts: Alluri Sitarama Raju (ASR), a tribal-dominated district in the state’s northern hill tracts, recorded markedly fewer hypertension and diabetes cases than other districts in the same survey. Yadav attributed this to the district’s traditional lifestyle — natural food, regular physical labour — but was notably cautious in his framing, stating explicitly that a dedicated scientific study would be needed to establish whether and how the traditional lifestyle actually drives the lower disease burden, rather than asserting the causal claim outright. That caveat matters: cross-sectional comparisons of this kind are consistent with several explanations beyond lifestyle, including differences in the age structure of ASR’s population, under-detection due to service-access constraints in remote tribal terrain, or genuine protective dietary and activity patterns — and the minister’s own comment leaves the question open rather than settled.
How NCD 4.0 compares with earlier rounds
Andhra Pradesh has run this survey in successive rounds — NCD 3.0, reported mid-2025, screened a larger 4.9 crore individuals and found 40 lakh diabetes cases and 30 lakh hypertension cases. NCD 4.0 screened fewer people in absolute terms but found more hypertension cases (59.29 lakh vs 30 lakh) and more diabetes cases (48.15 lakh vs 40 lakh) than the previous round. Read together, the two rounds are consistent with — though do not on their own prove — either a genuinely rising burden of hypertension and diabetes in the state’s adult population, improved detection sensitivity in the newer round, or some combination of both; NSH could not verify from public sources alone which explanation predominates, and any of the three would be a reasonable, non-alarmist reading of the data.
Why it matters
Non-communicable diseases — chiefly cardiovascular disease, diabetes and cancer — now account for the majority of India’s disease burden, and hypertension and diabetes in particular remain substantially under-diagnosed in large parts of the country, with previous national surveys (LASI, NPCDCS data) repeatedly finding that a large share of hypertensive and diabetic Indians are unaware of their condition until it produces a complication. A state-wide screening programme that reaches 87 per cent of its target population and converts more than 22 lakh previously undetected hypertension and diabetes cases into people now on treatment protocols represents a meaningful, measurable public-health intervention rather than a symbolic one — the value of NCD screening programmes lies specifically in this conversion of undiagnosed to diagnosed-and-treated, since early treatment of hypertension and diabetes measurably reduces downstream heart attack, stroke, kidney failure and blindness risk. The programme’s cancer-screening arm, while producing far fewer confirmed cases than suspected ones, has still identified more than 7,600 confirmed cancers across the three screened types and moved those patients into oncology care pathways at district hospitals — cancers that, detected at a later, symptomatic stage, would typically carry substantially worse prognoses and higher treatment costs. For a state that has repeatedly framed its healthcare strategy around large-scale, technology-assisted public screening (a strategy that also underpins the AI and genomics-based precision oncology initiative AP announced with AstraZeneca in July, discussed in the exclusion ledger below), NCD 4.0’s conclusion is a genuine, if unglamorous, public-health achievement — its real test now lies in whether the state can sustain treatment adherence among the newly diagnosed over the months and years ahead, a harder and less visible task than the screening itself.
– Dr Kanaka Durga Chandu
Key facts
- Survey period: 17 September 2025 to 31 August 2026; 3,71,86,846 people screened, 86.97% of targeted population
- 59.29 lakh hypertension cases found (11.79 lakh new); 48.15 lakh diabetes cases found (10.72 lakh new)
- Suspected cancers: 22,110 oral, 14,822 breast, 18,837 cervical; confirmed after further testing: 2,026 oral, 3,571 breast, 2,076 cervical
- ASR (Alluri Sitarama Raju) district recorded comparatively fewer hypertension/diabetes cases; minister called for further scientific study before drawing lifestyle conclusions
- Predecessor round, NCD 3.0 (reported 2025), screened 4.9 crore people and found 30 lakh hypertension and 40 lakh diabetes cases — fewer cases than NCD 4.0 despite screening more people
